Pfizer PFE Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| —— | —— | $9.87B— | $10.79B— | $7.91B— | ||
| $6.59B-4.5% | $6.59B-6.0% | $6.7B-2.8% | $6.79B+1.4% | $6.89B+5.4% | ||
| $901M+8.9% | $799M-8.9% | $751M-8.5% | $824M+18.1% | $827M+29.2% | ||
| -$1.48B+36.2% | -$2.13B-1.5% | -$2.1B+41.2% | -$1.81B+43.3% | -$2.32B+29.3% | ||
| —— | $263M+141% | $224.5M+4,590% | $186M+256% | $147.5M+163% | ||
| —— | -$561M-166% | -$207.25M-122% | $146.5M-85.5% | $500.25M-54.1% | ||
| —— | -$469M+54.2% | -$607.5M+27.9% | -$746M-12.8% | -$884.5M-84.0% | ||
| —— | -$1.29B+61.9% | -$1.81B+23.5% | -$2.33B-71.8% | -$2.86B-722% | ||
| —— | -$3.67B-17.7% | -$3.53B-61.3% | -$3.39B-169% | -$3.25B-878% | ||
| —— | -$2.81B-109% | -$2.44B-94.5% | -$2.08B-78.3% | -$1.71B-59.4% | ||
| $12.57B-10.2% | $12.29B-3.6% | $13.66B+21.3% | $15.77B+97.0% | $13.99B— | ||
| $2.5B-9.7% | $2.63B-9.6% | $2.7B-11.0% | $2.75B-13.9% | $2.77B-20.2% | ||
| -$3.84B— | -$1.35B— | —— | —— | —— | ||
| -$8.53B+51.1% | -$10.9B+36.4% | -$16.01B-143% | -$18.17B— | -$17.44B— | ||
| $67M— | $41M— | $7M— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $2.68B-15.4% | $2.74B-15.1% | $3.15B+8.9% | $3.16B+7.1% | $3.17B+43.1% | ||
| —— | -$469M+54.2% | -$607.5M+27.9% | -$746M-12.8% | -$884.5M-84.0% | ||
| —— | -$2.81B-109% | -$2.44B-94.5% | -$2.08B-78.3% | -$1.71B-59.4% | ||
| —— | —— | —— | —— | —— | ||
| —— | -$1.29B+61.9% | -$1.81B+23.5% | -$2.33B-71.8% | -$2.86B-722% | ||
| $603M-70.9% | $470M-79.2% | $2.16B-32.6% | $2.58B-11.5% | $2.07B-44.7% | ||
| —— | —— | —— | —— | —— | ||
| $730M— | $786M— | —— | —— | —— | ||
| $4.96B+11.4% | $5.27B+24.2% | $4.03B+0.9% | $4.31B+22.7% | $4.45B+35.9% | ||
| —— | —— | —— | —— | -$302M— | ||
| $14.1B+16.0% | $14.36B+41.7% | $16.48B+244% | $14.96B+33.3% | $12.16B-51.6% | ||
| $18.58B+150% | $17.96B+335% | $14.73B-38.3% | $12.92B-54.5% | $7.43B-77.9% | ||
| $1.1B-18.3% | $1.1B-30.3% | $533M-84.0% | $1.4B-33.8% | $1.35B-37.6% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $9.78B+2.1% | $9.77B+2.7% | $9.71B+2.7% | $9.64B+2.8% | $9.58B+2.8% | ||
| -$386M+12.1% | -$458M+2.3% | -$429M+9.3% | -$397M+21.2% | -$439M+24.4% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | $8.57B+76.6% | $12.95B+3,811% | ||
| —— | —— | —— | —— | $219M— | ||
| $4.61B+29.0% | $4.69B+30.0% | $4.1B+20.3% | $4.41B+15.9% | $3.57B+19.0% | ||
| —— | —— | —— | —— | $11.22B+120% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Pfizer generate?
- Pfizer (PFE) generated $12.6B in operating cash flow over the trailing twelve months.
- What is Pfizer's free cash flow?
- After $2.5B of capital expenditures, Pfizer's free cash flow was $12.5B over the trailing twelve months, up 26.6% year over year.
- Where does Pfizer's cash flow data come from?
- Every line is extracted from Pfizer's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
